Compare T-Mobile Us Inc (TMUS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs Zoetis Inc — how do they compare? T-Mobile Us Inc trades at $177.55 (market cap $194.89B), while Zoetis Inc trades at $73.91 (market cap $30.40B). The key difference: T-Mobile Us Inc is far larger — about 6.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| TMUS | ZTS | |
|---|---|---|
Market Cap | $194.89B | $30.40B |
Sector | Media | Health |
52-Week High | $241.67 | $150.61 |
52-Week Low | $167.65 | $71.91 |
Enterprise Value | $311.51B | $37.96B |
Dividend Yield | 2.25% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement (+0.09%) amid a bearish technical signal. The company demonstrates strong fundamentals with $88.3B revenue (2025) and consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80% buy ratings and a $233.20 consensus target, though technical indicators show near-term resistance at $183. Recent developments include CFO transition planning and institutional accumulation by California State Teachers Retirement System.
TMUS presents a compelling growth story with solid profitability metrics and analyst support, though technical weakness and competitive pressures warrant caution. The stock's 28% upside to consensus target offers potential, but investors must weigh strong cash flow generation against rising debt levels and sector-wide pricing pressures evident in recent broadband repricing trends.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
